国药股份(600511) - 2023 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2023 was ¥11,226,301,799.68, representing a year-on-year increase of 1.50%[4] - The net profit attributable to shareholders for Q1 2023 was ¥414,428,624.82, reflecting a growth of 10.86% compared to the same period last year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥412,594,479.98, an increase of 11.99% year-on-year[4] - The basic and diluted earnings per share for Q1 2023 were both ¥0.5493, up by 10.86% from the previous year[5] - The company reported a net profit margin improvement, with net profit for the quarter expected to be higher than the previous year, although specific figures were not disclosed[16] - The net profit for Q1 2023 was CNY 450,428,720.64, an increase of 10% compared to CNY 409,527,036.98 in Q1 2022[18] - The company reported a total profit of CNY 574,092,850.97, which is an increase of 9.3% from CNY 524,834,951.41 in the same quarter last year[18] - Total comprehensive income for the period was CNY 454,509,100.02, compared to CNY 409,330,053.15 in the previous year, reflecting an increase of about 11%[19] - The company reported a total comprehensive income of CNY 283,206,166.14, up from CNY 241,844,242.71 in the previous year, marking an increase of approximately 17.1%[27] Assets and Liabilities - The total assets at the end of Q1 2023 amounted to ¥29,973,102,161.98, a 1.23% increase from the end of the previous year[5] - The total assets as of March 31, 2023, amounted to RMB 29,973,102,161.98, up from RMB 29,609,041,999.59 at the end of 2022, representing a growth of approximately 1.2%[14] - Total liabilities decreased to RMB 13,659,123,044.34 from RMB 13,749,571,981.97, a reduction of about 0.7%[14] - The total liabilities decreased to CNY 9,040,422,614.32 in Q1 2023 from CNY 10,069,654,647.71 in Q1 2022, a reduction of about 10.2%[25] - The equity attributable to shareholders at the end of Q1 2023 was ¥14,633,316,663.59, which is a 2.94% increase compared to the end of the previous year[5] - The company's total equity increased to CNY 12,146,291,487.66 in Q1 2023 from CNY 11,863,085,321.52 in Q1 2022, reflecting a growth of approximately 2.4%[25] Cash Flow - The net cash flow from operating activities for Q1 2023 was negative at -¥1,144,417,344.84, indicating a significant cash outflow[4] - Cash flow from operating activities showed a net outflow of CNY -1,144,417,344.84, an improvement from CNY -1,309,048,043.82 in the previous year[21] - The net cash flow from financing activities was CNY 161,784,331.64 in Q1 2023, compared to a negative cash flow of CNY -134,322,698.79 in Q1 2022[22] - The cash inflow from financing activities was CNY 372,033,932.97, compared to CNY 346,761,757.81 in the previous year, representing an increase of about 7.3%[21] - The cash inflow from financing activities was CNY 4,622,866,991.24, an increase from CNY 3,899,604,840.39 in the same quarter last year, showing a growth of about 18.5%[28] - The company experienced a decrease in cash outflow from financing activities, which totaled CNY 5,651,665,054.86, compared to CNY 5,124,025,846.95 in Q1 2022, indicating a rise of approximately 10.3%[28] Operational Metrics - Total operating costs for Q1 2023 were RMB 10,721,710,525.39, compared to RMB 10,588,273,902.20 in Q1 2022, reflecting an increase of about 1.3%[16] - The total revenue from operating activities was CNY 11,269,856,654.00, down from CNY 11,677,534,959.21 in the previous year, representing a decrease of approximately 3.5%[21] - The total revenue from operating activities was CNY 5,368,466,798.45, compared to CNY 5,219,032,090.91 in the same period last year, indicating a year-over-year increase of about 2.86%[28] - The company recorded investment income of CNY 80,674,195.75, up from CNY 54,601,163.95, indicating a growth of approximately 47.7%[18] - Research and development expenses increased to CNY 16,684,728.20, up from CNY 13,439,599.79, reflecting a growth of about 24%[18] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 58,530[8] - The largest shareholder, China National Pharmaceutical Group Co., Ltd., held 54.72% of the shares[9]